Thalidomide and thrombosis in patients with multiple myeloma

Haematologica

Volumn 86, Issue 10, 2001, Pages 1108-1109

  Camba, L ^a   Peccatori, J ^a   Pescarollo, A ^a   Tresoldi, M ^a   Corradini, P ^a   Bregni, M ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Multiple myeloma; Thalidomide; Thrombosis

Indexed keywords

DEXAMETHASONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; MULTIPLE MYELOMA; RELAPSE; RISK FACTOR; SALVAGE THERAPY; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; THROMBOSIS;

EID: 0034766028     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Antitumour activity of thalidomide in refractory multiple myeloma
2. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
3. Thalidomide treatment of resistant or relapsed multiple myeloma patients
4. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
5. Deep vein thrombosis and thalidomide therapy for multiple myeloma
6. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
7. Deep-vein thrombosis
8. Thalidomide and thrombosis
9. Acquired thrombophilic syndromes
10. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade